

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

BF

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/48122 A2

(51) International Patent Classification⁷: C07D 285/00

(21) International Application Number: PCT/US01/47894

(22) International Filing Date:
11 December 2001 (11.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/255,658 14 December 2000 (14.12.2000) US

(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL,
INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ
08869-0602 (US)

(72) Inventors: BAXTER, Ellen, W.: 148 North Keswick Av-
enue, Glenside, PA 19038 (US); NORTEY, Samuel, O.;
7423 Euston Road, Elkins Park, PA 19027 (US); REITZ,
Allen, B.: 109 Greenbriar Road, Lansdale, PA 19446 (US).

(74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, NJ 08933
(US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/48122 A2

(54) Title: BENZAMIDINE DERIVATIVES

(57) Abstract: Benzamidine derivatives are useful delta-opioid receptor modulators, agonists useful as analgesics and antagonists useful as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medica-
ments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of
respiratory diseases.

BENZAMIDINE DERIVATIVES



FIELD OF THE INVENTION

The present invention is directed to delta-opioid receptor modulators and methods for use thereof. More particularly, the present invention is directed to

- 5 benzamidine derivatives which are delta-opioid receptor agonists or antagonists and methods for use thereof.



BACKGROUND OF THE INVENTION

WO 97/23466 describes compounds as having an analgesic effect of a general and one preferred formula:




10


WO 98/28270 describes compounds as having an analgesic effect of a general and one preferred formula:




WO 98/28275 describes compounds as having an analgesic effect of a general and one preferred formula:



- Amide derivatives of 3-aminotropane have been prepared and described
 5 as having potential pharmacological activity, Gutkowska, B., et al., *Acta Pol. Pharm.*, 1984, 41(6), 613-617, of the formula:




WO 93/15062 describes compounds as delta-opioid (δ -opioid) and mu-opioid (μ -opioid) receptor agonists of (approximately) the general formula:



The foregoing reference compounds have been described as either δ -opioid or μ -opioid receptor agonists or antagonists.

United States Patent 3,793,322 describes compounds of the general


5 formula:



wherein R and R' are hydrogen, lower alkyl, hydroxy, lower alkoxy, halogen or trifluoromethyl and may be the same or different; R'' is lower alkyl, lower alkenyl, cycloalkyl, or phenyl, and R''' is hydrogen, lower alkyl, lower alkenyl, carboalkoxy, carboalkoxyalkyl, formyl, phenyl, halophenyl, cinnamyl, benzyl or benzhydryl as having hypoglycemic activity. The lower alkyl, lower alkoxy and lower alkenyl groups may be branched or straight chained and contain up to 6 carbon atoms. The cycloalkyl groups contain from 3 to 7 carbon atoms in the ring which may also carry a lower alkyl substituent. The carboalkoxy groups contain alkyl groups having from 1 to 5 carbon atoms and include carbomethoxy, carbethoxy, carbopropoxy, carbobutoxy and the like. Desirably, R and R' are lower alkyl, preferably methyl, or halogen, preferably chloro; R may be hydrogen and R' is then chloro, lower alkyl, preferably methyl, or


- trifluoromethyl; R'' is lower alkyl, preferably isobutyl, and R''' is carbethoxy. Exemplified compounds include those wherein R is selected from hydrogen, chlorine, fluorine or methyl; R' is selected from hydrogen, chlorine, fluorine, methyl, methoxy, hydroxy or trifluoromethyl; R'' is selected from hydrogen, chlorine, fluorine, methyl, ethyl, *n*-propyl, *n*-butyl, *i*-butyl, *i*-amyl, *n*-hexyl, allyl, cyclohexyl, phenyl or 3,4-dimethylphenyl; R''' is selected from hydrogen, methyl, ethyl, *n*-hexyl, allyl, phenyl, 4-Cl-phenyl, benzhydryl, benzyl, 2,4-Cl₂-benzyl, 2,3,4-(MeO)₃-benzyl, COOEt or CHO.

United States Patent 3,962,248 describes compounds of the formula:




10

wherein A signifies the structure



Z1




Z2;

- R₁ is hydrogen, alkoxyalkyl of 2 to 6 carbon atoms in the aggregate thereof, alkyl of 1 to 4 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms or acyloxyalkyl of 3 to 22 carbon atoms in the aggregate thereof,
- 15 R₄ is hydrogen, alkyl, alkoxy or alkylthio, wherein the alkyl groups have 1 to 4 carbon atoms, halogen or trifluoromethyl; when A denotes Z1, X is a -CH₂-, -O-, -S-, -NH or -N-alkyl group wherein the alkyl group has 1 to 3 carbon atoms, R₂ is hydrogen, dialkylamino-sulphonyl, alkyl-sulphonyl, wherein the alkyl groups have 1 to 4 carbon atoms, alkoxy or alkylthio of 1 to 4 carbon atoms, halogen,

nitro, trifluoromethylsulphonyl, trifluoromethoxy, trifluoromethylthio, acetyl, cyano or trifluoromethyl, and R_3 is hydrogen, halogen or alkyl of 1 to 4 carbon atoms, or when A denotes Z2, X is a $-CH_2-$ or $-S-$ group as having neuroleptic activity.

- 5 The synthesis and binding affinities for 4-Diarylaminotropane compounds of the general formula:



- wherein R is hydrogen, methyl, propyl, hexyl, 2-ethylbutyl, allyl, 3,3-dimethallyl, cyclohexylmethyl, phenethyl, phenylpropyl, 2,2-diphenylethyl, 3,4-dimethoxyphenethyl, 4-fluorophenethyl, 2-furylmethyl; 3,4-methylenedioxybenzyl, cyano and X is *N,N*-dimethylamino, *N,N*-diethylamino, *N,N*-dipropylamino, *N*-methyl,*N*-ethylamino, *N*-methyl,*N*-propylamino, *N*-methyl,*N*-phenylamino, *N*-ethyl,*N*-(4-methyl)benzylamino, *N*-butyl,*N*-ethylamino, *N*-butyl,*N*-propylamino, 15 [*N*-ethyl,*N*-(2-methyl)allyl]amino, hydroxy, *O*-*t*-butyl and 1-pyrrolidinyl; and, Y is hydrogen, methoxy and methylthio as δ -opioid agonists have been described (Boyd, R.E., Carson, J.R., Codd, E.E., Gauthier, A.D., Neilson, L.A and Zhang, S-P., *Biorg. Med. Chem. Lett.*, **2000**, 10: 1109-1111).

- 4-[(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino]-
20 *N,N*-diethylbenzamides have also been described as selective δ -opioid ligands (Thomas, J.B., Atkinson, R.N., Rothman, R.B., Burgess, J.P., Mascarella, S.W., Dersch, C.M., Xu, H. and Carroll, F.I., *Biorg. Med. Chem. Lett.*, **2000**, 10: 1281-1284).


The benzamidine derivatives of the present invention have not been

previously described as δ -opioid receptor modulators.

Accordingly, it is an object of the present invention to provide benzamidine derivatives which are δ -opioid receptor modulators. It is also an object of the present invention to provide benzamidine derivatives which are δ -opioid receptor selective agonists useful as analgesics having reduced side-effects. It is another object of the present invention to provide δ -opioid receptor antagonists useful for treating immune disorders, inflammation, neurological conditions, psychiatric conditions, drug abuse, alcohol abuse, gastritis, diarrhea, cardiovascular disorders or respiratory disorders. It is a further object of the present invention to provide a method for treating a disorder modulated by the δ -opioid receptor.

SUMMARY OF THE INVENTION

The present invention provides benzamidine derivatives of Formula (I):



Formula I

wherein:

X is a substituent selected from the group consisting of S and O;

Z is a substituent selected from the group consisting of O(R₅) and N(R₆)(R₇);

the moiety -C(X)Z is substituted on the phenyl at the 3 or 4 position;

n is an integer from 1 to 2;

R₁ is a substituent selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy(C₁₋₆)alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkyl(C₁₋₆)alkoxycarbonyl, formyl, aryl, aryl(C₁₋₆)alkyl, diaryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl; wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₁₋₄alkoxy, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy;

R₂ and R₃ are substituents independently selected from the group consisting of hydrogen and C₁₋₆alkyl;

Ar is aryl optionally substituted with one to three substituents selected from R₄;

R₄ is a substituent selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkoxy, aryl, aryl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, cyano, hydroxy, nitro, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy; alternatively, two R₄ substituents may be fused together on adjacent carbon atoms to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

R₅ is a substituent selected from C₁₋₆alkyl; and,

R₆ and R₇ are substituents independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₇cycloalkyl, aryl and aryl(C₁₋₆)alkyl, wherein cycloalkyl and aryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₁₋₄alkoxy, C₃₋₇cycloalkyl, trihaloC₁₋₃alkyl and trihaloC₁₋₃alkoxy; alternatively, R₆ and R₇ may be fused together to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

DETAILED DESCRIPTION OF THE INVENTION

We have discovered that the benzamidine derivatives of the present invention are useful δ -opioid receptor modulators, particularly δ -opioid receptor agonists.

An embodiment of the present invention includes those compounds wherein preferably, X is O.

Embodiments of the present invention include compounds wherein preferably, R_1 is a substituent selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxycarbonyl, formyl, aryl, aryl(C_{1-6})alkyl, diaryl(C_{1-6})alkyl and heteroaryl(C_{1-6})alkyl; wherein aryl is optionally substituted with one to three substituents independently selected from halogen and C_{1-4} alkoxy). More preferably, R_1 is a substituent selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl, *n*-butyl, *n*-hexyl, allyl, propenyl, cinnamyl, methoxy(C_{1-3})alkyl, ethoxy(C_{1-3})alkyl, propoxy(C_{1-3})alkyl, C_{1-3} alkoxycarbonyl, formyl, phenyl (optionally substituted with one to two substituents independently selected from halogen), benzyl (optionally substituted with one to three substituents independently selected from halogen and C_{1-4} alkoxy), benzhydryl, phenyl(C_{2-3})alkyl, furyl(C_{1-3})alkyl, thienyl(C_{1-3})alkyl, pyrrolyl(C_{1-3})alkyl, pyrrolinyl(C_{1-3})alkyl, oxazolyl(C_{1-3})alkyl, thiazolyl(C_{1-3})alkyl, imidazolyl(C_{1-3})alkyl, imidazolinyl(C_{1-3})alkyl, pyrazolyl(C_{1-3})alkyl, pyrazolinyl(C_{1-3})alkyl, isoxazolyl(C_{1-3})alkyl, isothiazolyl(C_{1-3})alkyl, pyridinyl(C_{1-3})alkyl, pyridazinyl(C_{1-3})alkyl, pyrimidinyl(C_{1-3})alkyl and pyrazinyl(C_{1-3})alkyl. Most preferably, R_1 is a substituent selected from the group consisting of hydrogen, ethyl, *n*-propyl, allyl, methoxyethyl, phenyl, benzyl, phenethyl and 2-thienylethyl.

Embodiments of the present invention also include compounds wherein preferably, R_2 and R_3 are substituents independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl and *n*-butyl. More preferably, R_2 and R_3 are substituents independently selected from the group consisting of hydrogen and methyl.

Embodiments of the present invention further include compounds wherein preferably, Ar is a substituent selected from the group consisting of phenyl and naphthalenyl optionally substituted with one to three substituents selected from R₂. More preferably, Ar is phenyl optionally substituted with one
 5 to three substituents selected from R₄. Most preferably, Ar is phenyl optionally substituted with one to two substituents independently selected from R₄.

An embodiment of the present invention includes compounds wherein preferably, R₄ is a substituent selected from the group consisting of halogen, C₁₋₄alkoxy and trihaloC₁₋₄alkyl. More preferably, R₄ is a substituent selected
 10 from the group consisting of chlorine, fluorine, bromine, methoxy, ethoxy, propoxy, butoxy, trifluoromethyl and trifluoroethyl. Most preferably, R₄ is a substituent selected from the group consisting of chlorine, fluorine, bromine, methoxy and trifluoromethyl.

An embodiment of the present invention also includes compounds
 15 wherein preferably, R₅ is a substituent selected from the group consisting of methyl, ethyl, *n*-propyl and *n*-butyl. More preferably, R₅ is methyl.

An embodiment of the present invention further includes compounds wherein preferably, R₆ and R₇ are substituents independently selected from the group consisting of hydrogen and C₁₋₆alkyl. More preferably, R₆ and R₇ are
 20 substituents independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl and *n*-butyl. Most preferably, R₆ and R₇ are substituents independently selected from the group consisting of ethyl and *n*-propyl.

Exemplifying the invention is a compound of Formula (I) selected from
 Table 1:

25

Table 1

Cpd.	Compound Name
1	<i>N,N</i> -diethyl-4-[(4-ethyl-1-piperazinyl)(phenylimino)methyl]-benzamide;
2	<i>N,N</i> -diethyl-4-[(4-ethyl-1-piperazinyl)((3-methoxyphenyl)imino)methyl]-benzamide;
3	4-[[[(3-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]- <i>N,N</i> -diethylbenzamide;
4	4-[[[(3-bromophenyl)imino](4-ethyl-1-piperazinyl)methyl]- <i>N,N</i> -diethylbenzamide;
5	4-[[[(3-bromophenyl)imino](4-ethyl-1-piperazinyl)methyl]- <i>N,N</i> -dipropylbenzamide;

- 6 4-[[[(2-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-*N,N*-diethyl-benzamide;
- 7 4-[[[(2-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-*N,N*-dipropyl-benzamide;
- 8 4-[[[(4-ethyl-1-piperazinyl)][(3-fluorophenyl)imino]methyl]-*N,N*-dipropyl-benzamide;
- 9 *N,N*-diethyl-4-[[[(4-ethyl-1-piperazinyl)][(3-fluorophenyl)imino]methyl]-benzamide;
- 10 *N,N*-diethyl-4-[[[(4-ethyl-1-piperazinyl)][(2-fluorophenyl)imino]methyl]-benzamide;
- 11 4-[[[(4-ethyl-1-piperazinyl)][(2-fluorophenyl)imino]methyl]-*N,N*-dipropyl-benzamide;
- 12 4-[[[(3,5-dichlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-*N,N*-dipropyl-benzamide;
- 13 4-[[[(3,5-dichlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-*N,N*-diethyl-benzamide;
- 14 4-[[[(3-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-*N,N*-diethyl-benzamide;
- 15 *N,N*-diethyl-4-[(phenylimino)[4-(2-propenyl)-1-piperazinyl]methyl]-benzamide;
- 16 4-[(*E*)-[(2*S*,5*R*)-2,5-dimethyl-4-(2-propenyl)piperazinyl](phenylimino)methyl]-*N,N*-diethyl-benzamide;
- 17 *N,N*-diethyl-4-[(phenylimino)[4-(phenylmethyl)-1-piperazinyl]methyl]-benzamide;
- 18 4-[[[(2-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-*N,N*-diethyl-benzamide;
- 19 4-[[[(2-chlorophenyl)imino][4-(2-propenyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;
- 20 4-[[[(2-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;
- 21 4-[[[(2-chlorophenyl)imino][4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;
- 22 *N,N*-diethyl-4-[(phenylimino)[4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-benzamide;
- 23 *N,N*-diethyl-4-[[4-(phenylmethyl)-1-piperazinyl][2-(trifluoromethyl)phenyl]imino]methyl]-benzamide;
- 24 *N,N*-diethyl-4-[[4-(2-phenylethyl)-1-piperazinyl][2-(trifluoromethyl)phenyl]imino]methyl]-benzamide;
- 25 4-[[[(2-chlorophenyl)imino][4-(2-phenylethyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;
- 26 *N,N*-diethyl-4-[[4-(2-methoxyethyl)-1-piperazinyl][2-(trifluoromethyl)phenyl]imino]methyl]-benzamide;
- 27 4-[[[(2-chlorophenyl)imino][4-(2-methoxyethyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;

- 28 4-[[[(4-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;
- 30 4-[[[(3-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 31 4-[[[(3-bromophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 32 4-[[[(2-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 33 4-[(4-ethyl-1-piperazinyl)[(3-fluorophenyl)imino]methyl]-benzoic acid methyl ester;
- 34 4-[[[(2-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 35 4-[[[(2-chlorophenyl)imino](4-phenyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 36 4-[(4-ethenyl-1-piperazinyl)(phenylimino)methyl]-benzoic acid methyl ester;
- 37 4-[(phenylimino)[4-(phenylmethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 38 4-[[[(4-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 39 4-[[[(2-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 40 4-[[[(2-chlorophenyl)imino][4-(2-phenylethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 41 4-[[[4-(2-phenylethyl)-1-piperazinyl][[2-(trifluoromethyl)phenyl]imino]methyl]-benzoic acid methyl ester;
- 42 4-[(phenylimino)[4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 43 4-[[[(2-chlorophenyl)imino][4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 44 4-[[[4-(2-methoxyethyl)-1-piperazinyl][[2-(trifluoromethyl)phenyl]imino]methyl]-benzoic acid methyl ester;
- 45 4-[[[(2-chlorophenyl)imino][4-(2-methoxyethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 46 4-[(4-ethyl-1-piperazinyl)(phenylimino)methyl]-benzoic acid methyl ester;
- 47 4-[(4-ethyl-1-piperazinyl)[(3-methoxyphenyl)imino]methyl]-benzoic acid methyl ester;
- 48 4-[(4-ethyl-1-piperazinyl)[(2-methoxyphenyl)imino]methyl]-benzoic acid methyl ester;
- 49 4-[[[(3,5-dichlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 50 4-[[[(3-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-benzoic acid methyl ester;


- 51 4-[(*E*)-{(2*S*,5*R*)-2,5-dimethyl-4-(2-propenyl)piperazinyl}(phenylimino)methyl]-benzoic acid methyl ester;
- 52 3-[[{(2-chlorophenyl)imino}[4-(2-propenyl)-1-piperazinyl]methyl]-*N,N*-diethyl-benzamide;
- 53 *N,N*-diethyl-3-[(phenylimino)[4-(2-propenyl)-1-piperazinyl]methyl]-benzamide;
- 54 3-[[{(2-chlorophenyl)imino}[4-(2-propenyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 55 3-[(phenylimino)[4-(2-propenyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 56 *N,N*-diethyl-4-[[hexahydro-4-(2-phenylethyl)-1*H*-1,4-diazepin-1-yl](phenylimino)methyl]-benzamide;
- 57 4-[[{(2-chlorophenyl)imino}[hexahydro-4-(2-phenylethyl)-1*H*-1,4-diazepin-1-yl]methyl]-*N,N*-diethyl-benzamide;
- 58 4-[[hexahydro-4-(2-phenylethyl)-1*H*-1,4-diazepin-1-yl](phenylimino)methyl]-benzoic acid methyl ester;
- or,
- 59 4-[[{(2-chlorophenyl)imino}[hexahydro-4-(2-phenylethyl)-1*H*-1,4-diazepin-1-yl]methyl]-benzoic acid methyl ester;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

- Representative Chemical Abstracts Service (CAS) Index-like names for the compounds of the present invention were derived using the ACD/LABS SOFTWARE™ Index Name Pro Version 4.0 nomenclature software program
- 5 provided by Advanced Chemistry Development, Inc., Toronto, Ontario, Canada.

In another view, exemplified benzamidine derivatives of the present invention include those compounds shown in Table 2 having the formula:

TABLE 2



wherein n, R₁, R₂, R₃, R₄ and X are selected from:

Cpd	n	R ₁	R ₂	R ₃	R ₄	-C(O)X
1	1	Et	H	H	---	-4-C(O)N(Et) ₂ ;
2	1	Et	H	H	3-MeO	-4-C(O)N(Et) ₂ ;
3	1	Et	H	H	3-Cl	-4-C(O)N(Et) ₂ ;
4	1	Et	H	H	3-Br	-4-C(O)N(Et) ₂ ;
5	1	Et	H	H	3-Br	-4-C(O)N(Pr) ₂ ;
6	1	Et	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
7	1	Et	H	H	2-Cl	-4-C(O)N(Pr) ₂ ;
8	1	Et	H	H	3-F	-4-C(O)N(Pr) ₂ ;
9	1	Et	H	H	3-F	-4-C(O)N(Et) ₂ ;
10	1	Et	H	H	2-F	-4-C(O)N(Et) ₂ ;
11	1	Et	H	H	2-F	-4-C(O)N(Pr) ₂ ;
12	1	Et	H	H	3,5-Cl ₂	-4-C(O)N(Pr) ₂ ;
13	1	Et	H	H	3,5-Cl ₂	-4-C(O)N(Et) ₂ ;
14	1	Pr	H	H	3-Cl	-4-C(O)N(Et) ₂ ;
15	1	Allyl	H	H	---	-4-C(O)N(Et) ₂ ;
16	1	Allyl	2-Me	5-Me	---	-4-C(O)N(Et) ₂ ;
17	1	Benzyl	H	H	---	-4-C(O)N(Et) ₂ ;
18	1	Allyl	H	H	3-Cl	-4-C(O)N(Et) ₂ ;
19	1	Allyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
20	1	Benzyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
21	1	2-(2-thienyl)ethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
22	1	2-(2-thienyl)ethyl	H	H	---	-4-C(O)N(Et) ₂ ;
23	1	Benzyl	H	H	2-CF ₃	-4-C(O)N(Et) ₂ ;
24	1	Phenethyl	H	H	2-CF ₃	-4-C(O)N(Et) ₂ ;
25	1	Phenethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
26	1	2-(methoxy)ethyl	H	H	2-CF ₃	-4-C(O)N(Et) ₂ ;
27	1	2-(methoxy)ethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
28	1	Benzyl	H	H	4-Cl	-4-C(O)N(Et) ₂ ;
29	1	Et	H	H	3-Cl	-4-C(O)OMe;

30	1	Et	H	H	3-Br	-4-C(O)OMe;
31	1	Et	H	H	2-Cl	-4-C(O)OMe;
32	1	Et	H	H	3-F	-4-C(O)OMe;
33	1	Et	H	H	2-F	-4-C(O)OMe;
34	1	Pr	H	H	2-Cl	-4-C(O)OMe;
35	1	Ph	H	H	2-Cl	-4-C(O)OMe;
36	1	Allyl	H	H	---	-4-C(O)OMe;
37	1	Benzyl	H	H	---	-4-C(O)OMe;
38	1	Benzyl	H	H	4-Cl	-4-C(O)OMe;
39	1	Benzyl	H	H	2-Cl	-4-C(O)OMe;
40	1	Phenethyl	H	H	2-Cl	-4-C(O)OMe;
41	1	Phenethyl	H	H	2-CF ₃	-4-C(O)OMe;
42	1	2-(2-thienyl)ethyl	H	H	---	-4-C(O)OMe;
43	1	2-(2-thienyl)ethyl	H	H	2-Cl	-4-C(O)OMe;
44	1	2-(methoxy)ethyl	H	H	2-CF ₃	-4-C(O)OMe;
45	1	2-(methoxy)ethyl	H	H	2-Cl	-4-C(O)OMe;
46	1	Et	H	H	---	-4-C(O)OMe;
47	1	Et	H	H	3-MeO	-4-C(O)OMe;
48	1	Et	H	H	2-MeO	-4-C(O)OMe;
49	1	Et	H	H	3,5-Cl ₂	-4-C(O)OMe;
50	1	Pr	H	H	3-Cl	-4-C(O)OMe;
51	1	Allyl	2-Me	5-Me	---	-4-C(O)OMe;
52	1	Allyl	H	H	2-Cl	-3-C(O)N(Et) ₂ ;
53	1	Allyl	H	H	---	-3-C(O)N(Et) ₂ ;
54	1	Allyl	H	H	2-Cl	-3-C(O)OMe;
55	1	Allyl	H	H	---	-3-C(O)OMe;
56	2	Phenethyl	H	H	---	-4-C(O)N(Et) ₂ ;
57	2	Phenethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
58	2	Phenethyl	H	H	---	-4-C(O)OMe;
or,						
59	2	Phenethyl	H	H	2-Cl	-4-C(O)OMe;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

Instant compounds of the invention may also be present in the form of a pharmaceutically acceptable salt. The pharmaceutically acceptable salt generally takes a form in which the basic nitrogen is protonated with an inorganic or organic acid. Representative organic or inorganic acids include

5 hydrochloric, hydrobromic, hydroiodic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexanesulfamic, salicylic, saccharic or trifluoroacetic.

10 Where the compounds according to this invention are chiral, they may accordingly exist as enantiomers. In addition, the compounds may exist as diastereomers. It is to be understood that all such stereoisomers and racemic mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as

15 polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.

It is intended that the definition of any substituent or variable at a

20 particular location in a molecule be independent of its definitions elsewhere in that molecule. It is understood that substituents and substitution patterns on the compounds of this invention can be selected by one of ordinary skill in the art to provide compounds that are chemically stable and that can be readily synthesized by techniques known in the art as well as those methods set forth

25 herein.

The terms used in describing the invention are commonly used and known to those skilled in the art. However, the terms that could have other meanings are hereinafter defined. These definitions apply to the terms as they are used throughout this specification, unless otherwise limited in specific

30 instances, either individually or as part of a larger group.

An "independently" selected substituent refers to a group of substituents, wherein the substituents may be different. Therefore, designated numbers of carbon atoms (e.g., C₁₋₈) shall refer independently to the number of carbon

atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

The term "alkyl" refers to straight and branched-chain alkyl radical groups and the term "alkylene" refers to a corresponding straight and branched-chain alkyl linking group. Similarly, the "alkenyl" and "alkynyl" refers to radical groups having straight and branched chains with 2 to 8 carbon atoms or any number within this range, wherein one or two double bonds or one triple bond is formed in the chain between adjacent members. The term "alkoxy" refers to O-alkyl groups where alkyl is as defined supra. The term cycloalkyl refers to a cyclic alkyl ring of five to seven carbon atom members. Examples of such cyclic alkyl rings include pentyl, hexyl or heptyl.

The term aryl refers to a single aromatic ring of six carbon members or a bicyclic aromatic ring of ten carbon members. Examples of such aryl rings include phenyl and naphthyl.

The term heteroaryl refers to an aromatic ring of five or six members wherein the ring has at least one heteroatom member. Suitable heteroatoms include nitrogen, oxygen or sulfur. In the case of five-membered rings, the heteroaryl ring contains one member of nitrogen, oxygen or sulfur and, in addition, may contain up to two additional nitrogens. In the case of six-membered rings, the heteroaryl ring may contain from one to three nitrogen atoms. For the case wherein the six member ring has three nitrogens, at most two nitrogen atoms are adjacent.

The terms " C_{1-6} alkoxy(C_{1-6})alkyl," "aryl(C_{1-6})alkyl," "diaryl(C_{1-6})alkyl" or "heteroaryl(C_{1-6})alkyl" refer to an alkylene group substituted at the terminal carbon with an alkoxy, aryl, diaryl or heteroaryl group, respectively. Similarly, the term " C_{1-6} alkoxycarbonyl" refers to a carbonyl linking group substituted with a terminal alkoxy group.

Whenever the term "alkyl" or "aryl" or either of their prefix roots appear in a name of a substituent (e.g., aryl(C_{1-6})alkyl) it shall be interpreted as including those limitations given above for "alkyl" and "aryl." Designated numbers of carbon atoms (e.g., C_{1-6}) shall refer independently to the number of carbon atoms in an alkyl or cycloalkyl moiety or to the alkyl portion of a larger substituent in which alkyl appears as its prefix root.

The term "halogen" shall include iodine, bromine, chlorine and fluorine.

The novel benzamidine derivative compounds of the present invention are useful δ -opioid receptor modulators. In particular, the instant benzamidine compounds are δ -opioid receptor selective agonists useful as analgesics
5 having reduced side-effects. Examples of pain intended to be within the scope of the present invention include, but are not limited to, centrally mediated pain, peripherally mediated pain, structural or soft tissue injury related pain, progressive disease related pain, neuropathic pain and acute pain such as caused by acute injury, trauma or surgery and chronic pain such as caused by
10 neuropathic conditions, diabetic peripheral neuropathy, post-herpetic neuralgia, trigeminal neuralgia, post-stroke pain syndromes or cluster or migraine headaches. The utility of the instant compounds as δ -opioid receptor selective agonists can be determined according to the procedures described herein.

Also, the compounds of the present invention are δ -opioid receptor
15 selective antagonists useful as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases, having reduced side-effects. The utility of the instant compounds as
20 δ -opioid receptor selective antagonists can be determined by those skilled in the art using established animal models.

An embodiment of the invention is a pharmaceutical composition comprising one or more compounds of this invention in association with a pharmaceutically acceptable carrier. Another embodiment is a pharmaceutical
25 composition made by mixing any of the compounds described above and a pharmaceutically acceptable carrier. A further embodiment is a process for making a pharmaceutical composition comprising mixing any of the compounds described above and a pharmaceutically acceptable carrier.

The present invention is also embodied by a pharmaceutical composition
30 comprising a combination of a δ -opioid receptor modulator compound of the present invention and a μ -opioid receptor modulator compound having a synergistic analgesic effect. The utility of the instant combination product can be determined by those skilled in the art using established animal models.

Suitable μ -opioid receptor modulator compounds for use in such a combination include, without limitation, the compounds alfentanil, allylprodine, alphaprodine, anileridine, benzyl-morphine, bezitramide, buprenorphine, butorphanol, clonitazene, cyclazocine, desomorphine, dextromoramide, 5 dezocine, diampromide, diamorphine, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydromorphine, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, 10 levophenacilmorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, 15 piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, diastereomers thereof, salts thereof, complexes thereof; and mixtures of any of the foregoing.

The present invention includes a method for treating a disorder modulated by the δ -opioid receptor. An embodiment of the present invention is 20 a method for treating pain modulated by a δ -opioid agonist. Another embodiment is a method for treating immune disorders, inflammation, neurological conditions, psychiatric conditions, drug abuse, alcohol abuse, gastritis, diarrhea, cardiovascular disorders or respiratory disorders modulated by a δ -opioid antagonist.

25 The present invention therefore provides a method for the use of the instant benzamidine derivatives as δ -opioid receptor modulators in a subject in need thereof which comprises administering any of the compounds as defined herein in a therapeutically effective dose to modulate the δ -opioid receptor. A compound may be administered to a subject in need of treatment by any 30 conventional route of administration including, but not limited to oral, nasal, sublingual, ocular, transdermal, rectal, vaginal and parenteral (i.e. subcutaneous, intramuscular, intradermal, intravenous etc.).

A therapeutically effective dose for use of the instant compounds or a

pharmaceutical composition thereof as a δ -opioid receptor selective agonist, δ -opioid receptor selective antagonist or in a combination δ -opioid/ μ -opioid receptor modulator product comprises a dose range of from about 0.01 mg to about 12,000 mg, in particular from about 0.1 mg to about 4000 mg or, more particularly from about 1 mg to about 2000 mg of active ingredient per day for an average (70 kg) human.

For oral administration, a pharmaceutical composition is preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the subject to be treated. Advantageously, compounds of the present invention may be administered in a single daily dose or the total daily dosage may be administered in divided doses of two, three or four times daily.

It is apparent to one skilled in the art that the therapeutically effective dose for active compounds of the invention or a pharmaceutical composition thereof will vary according to the desired effect. Therefore, optimal dosages to be administered may be readily determined and will vary with the particular compound used, the mode of administration, the strength of the preparation, and the advancement of the disease condition. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an appropriate therapeutic level.

Compounds of this invention may be administered in any of the foregoing compositions and dosage regimens or by means of those compositions and dosage regimens established in the art whenever use of the compounds of the invention as δ -opioid receptor modulators is required for a subject in need thereof.

The terms used in describing the invention are commonly used and known to those skilled in the art. As used herein, the following abbreviations have the indicated meanings:

Cpd	Compound
Et	Ethyl

	h	Hour
	Me	Methyl
	MeOH	Methanol
	min	Minute
5	Ph	Phenyl
	POCl ₃	Phosphorus oxychloride
	rt	Room temperature
	SOCl ₂	Thionyl chloride

General Synthetic Methods

- 10 Representative compounds of the present invention can be synthesized in accordance with the general synthetic methods described below and are illustrated in the schemes that follows. Since the schemes are an illustration, the invention should not be construed as being limited by the chemical reactions and conditions expressed. The preparation of the various starting materials used in the schemes is well within the skill of persons versed in the art.

Scheme 1 describes the preparation of certain target benzamide derivative compounds of the invention whereby a piperazine Compound **1a** underwent a condensation reaction with a benzoyl acid chloride Compound **1b**.

- 20 For Compound **1b**, the variable A may be selected from OH or Cl; X may be selected from O or S; and, Z may be selected from OR_s. An example of Compound **1b** is terephthalic acid monomethyl ester chloride. The condensation reaction was carried out in a base such as aqueous sodium hydroxide to give the amide Compound **1c**.

- 25 The amide Compound **1c** was then converted to the iminoylchloride Compound **1d** by treatment with phosphorus oxychloride. Upon reaction of the iminochloride Compound **1d** with a compound Ar(R₄)NH₂, such as aniline, the amidino ester Compound **1e** was formed.


- 30 The ester Compound **1e** was hydrolyzed with sodium hydroxide to the corresponding carboxylic acid which was then reacted with thionyl chloride to provide an acid chloride intermediate. The acid chloride intermediate was then reacted with a secondary amine such as, but not limited to, diethyl amine to produce the target amide Compound **1f**.

The functional groups in the target compounds may be varied as desired

- by those skilled in the art using either addition reactions in later steps or using various starting materials or reagents. For example, wherein the desired Ar group is naphthalenyl, the synthetic step for producing Compound 1e may be carried out by reacting Compound 1d with a compound of the formula
- 5 Ar(R₄)NH₂, wherein Ar is a naphthalenyl group. Other variable substituted and unsubstituted Ar groups known to one skilled in the art may also be used in this step to produce other compounds intended to be within the scope of the present invention. Similarly, the synthetic sequence may be carried out starting with a removable R₁ group such as methyl or BOC. At the conclusion of the
- 10 sequence shown in Scheme 1, the blocking group may be removed and replaced with the desired R₁ substituent.


Scheme 1 illustrates the method described above.

Scheme 1



- Scheme 2 illustrates the use of Weinreb's method to prepare other target benzamide derivative compounds of the invention; wherein a secondary amine HNR₆R₇ compound was activated with trimethylaluminum and reacted with ester Compound **1e** to directly give the target amide Compound **1f**.

Scheme 2




Scheme 3 illustrates a method whereby, in those cases where a

particular R_5 group may not be amenable to the reactions described in Scheme 1, the R_5 group may be interchanged to produce other target benzoic acid alkyl ester derivative compounds of the invention

In Scheme 3, the ester Compound **1e** was converted to another alkyl ester Compound **2a** (wherein the R_5 ester group may be further varied as desired) by hydrolysis of the ester Compound **1e** with sodium hydroxide to the corresponding carboxylic acid. The carboxylic acid was reacted with thionyl chloride to provide an acid chloride intermediate which was then reacted with an alkyl alcohol Compound HOR_5 to give the respective target Compound **2a**.

10

Scheme 3



Specific Synthetic Methods

Specific compounds which are representative of the invention may be prepared as per the following examples offered by way of illustration and not by way of limitation. No attempt has been made to optimize the yields obtained in any of the reactions. One skilled in the art would know how to increase such yields through routine variations in reaction times, temperatures, solvents and/or reagents.

Example 1

20

4-[[[(2-chlorophenyl)imino][4-(phenylmethyl)-

1-piperazinyl)methyl]-N,N-diethyl-benzamide (Compound **20**)

A solution of 1-benzyl piperazine (8.8 g, 0.05 mol) in dichloromethane (80 mL) was treated with sodium hydroxide solution (1N, 80 mL) and stirred for 15 min and was then treated with a solution of terephthalic acid monomethyl ester chloride (10 g, 0.05 mol) in dichloromethane (20 mL). The mixture was stirred

for 24 h, the organic layer was separated, washed with brine, dried (Na_2SO_4) and concentrated in vacuo to give an amide ester as a light yellow solid (17.7 g, 98 % yield).

5 The amide ester (4.0 g, 0.012 mol) was dissolved in phosphorus oxychloride (22.14 g, 0.14 mol) and water (0.51 mL) was added cautiously. The mixture was stirred for 5 min, and treated dropwise with 2-chloroaniline (1.66 g, 0.013 mol). The resultant yellow solution was stirred at 80°C for 24 h. The mixture was concentrated in vacuo, treated with cold water and 3N NaOH was added to pH 10 and extracted twice into dichloromethane. The combined
10 organic extracts were washed with brine, dried (Na_2SO_4) and concentrated in vacuo to give an amidine ester (4.0 g) as a syrup, which was used in the next step without further purification.

A solution of the amidine ester (3.6 g, 8.0 mmol) in 3N NaOH (12 mL), and methanol (6 mL) was stirred at 80°C for 24h, cooled and neutralized with
15 3N HCl to about pH 7 to give the respective carboxylate as a pale yellow solid. The carboxylate was dissolved in benzene (30 mL), treated with thionyl chloride (5.5 mL) and refluxed for 3 h. The mixture was concentrated in vacuo to give the crude acid chloride which was immediately dissolved in dichloromethane (12 mL), treated with 1N NaOH (12 mL) and cooled. A solution of diethylamine
20 (8 mL) in dichloromethane (4 mL) was added at 0-5°C. After addition, the mixture was stirred at room temperature for 18 h. The organic layer was washed with brine, dried (Na_2SO_4) and concentrated in vacuo. The residue was purified on a prep-500 HPLC using ethyl acetate:hexane:methanol (8:2:1) as eluents to give Compound 20 as a syrup (1.20 g). A representative sample
25 was converted to the oxalate salt in 2-propanol and recrystallized in the same solvent to give a pure sample. MS m/z 489(M^+); 491(M^{+2}). 300 MHz ^1H NMR (CDCl_3) δ 7.08 – 7.32 (m, 10H); 6.8 (t, 1H); 6.60 (t, 1H); 6.40 (d, 1H); 3.55 (s, 2H); 3.35 – 3.50 (m, 6H); 2.80 – 3.05 (m, 2H); 2.35 – 2.06 (m, 4H); 1.10 – 1.25 (m, 3H); 0.88 – 1.05 (m, 3H); Anal calcd. for $\text{C}_{29}\text{H}_{33}\text{ClN}_4\text{O} \cdot \text{C}_2\text{H}_2\text{O}_4 \cdot 0.2\text{H}_2\text{O}$: C, 63.90; H, 6.12; Cl, 6.08; N, 9.61. Found: C, 63.55; H, 5.90; Cl, 6.47; N, 9.34.
30

Example 2

Following the procedure of Example 1 and substituting the appropriate starting materials, reagents and solvents the following compounds were prepared:

Ex#	MS m/z (M^+)	MS m/z (M^{+2})
15	405	---
16	433	---
17	455	---
18	439	441
19	439	441
21	509	511
22	475	---
23	523	---
24	537	---
25	503	505
26	491	---
27	457	459
28	489	491
52	439	441
53	405	---
54	397	399
55	439	441
56	483	---
57	517	519
58	442	---
59	475	477

Example 3

4-[[[(3-chlorophenyl)imino](4-propyl-

1-piperazinyl)methyl]-*N,N*-diethyl-benzamide (Compound 14)

- A mixture of trimethylaluminum (2M/toluene, 2.41 mL, 4.8 mmol), diethylamine
 5 (0.51 mL, 4.8mmol) in dichloromethane (9 mL) was stirred for 4h at room
 temperature and treated with a solution of a 3-chloro amidine ester derivative
 (prepared as in Example 1, 0.55 g, 1.4mmol) in dichloromethane and heated to
 45°C for 28 h. The mixture was poured over ice, treated with 1N HCl (pH 1)
 and washed with dichloromethane. The aqueous layer was neutralized with 3N

NaOH and extracted with dichloromethane twice. The combined organic extracts were dried (Na_2SO_4) and concentrated in vacuo. The residue was purified by preparative TLC (5 x 1000 micron plates;

EtOAc:Hexane:MeOH: CH_2Cl_2 : NH_4OH ; 10:5:1:1:0.1) to give Compound **14** as a syrup. MS m/z 441(M^+); 443(M^{+2}). MS $m/z = 441(\text{M}^+ + \text{H})$. 300 MHz ^1H NMR (CDCl_3) δ 7.18 - 7.20 (m, 2H); 7.05 - 7.15 (m, 2H); 6.85-6.92 (m, 1H); 6.60-6.69 (m, 1H); 6.40-6.48 (m, 1H); 6.39 (s, 1H); 3.22-3.8 (m, 6H); 2.95 - 3.10 (m, 2H); 2.40 - 2.60 (m, 4H); 2.30 - 2.39 (t, 2H); 1.45 - 1.60 (m, 2H); 1.10 - 1.25 (m, 3H); 0.95 - 1.05 (M, 3H); 0.85 - 0.94 (t, 3H).

10

Example 4

Following the procedure of Example 3 and substituting the appropriate starting materials, reagents and solvents the following compounds were prepared:

Ex#	MS m/z (MH^+)	MS m/z (MH^{+2})
1	393	—
2	423	—
3	427	429
4	472	—
5	500	—
6	427	429
7	455	457
8	439	—
9	411	—
10	411	—
11	439	—
12	490	—
13	462	—

Example 5

4-[[[(2-chlorophenyl)imino][4-(phenylmethyl)-

1-piperazinyl]methyl]-benzoic acid methyl ester; (Compound **39**)

A solution of 1-benzyl piperazine (8.8 g, 0.05 mol) in dichloromethane (80 mL) was treated with sodium hydroxide solution (1N, 80 mL) and stirred for 15 min

and was then treated with a solution of terephthalic acid monomethyl ester chloride (10 g, 0.05 mol) in dichloromethane (20 mL). The mixture was stirred for 24 h, the organic layer was separated, washed with brine, dried (Na_2SO_4) and concentrated in vacuo to give an amide ester as a light yellow solid (17.7 g, 98 % yield).

The amide ester (4.0 g, 0.012 mol) was dissolved in phosphorus oxychloride (22.14 g, 0.14 mol) and water (0.51 mL) was added cautiously. The mixture was stirred for 5 min, and treated dropwise with 2-chloroaniline (1.66 g, 0.013 mol). The resultant yellow solution was stirred at 80°C for 24 h.

The mixture was concentrated in vacuo, treated with cold water and 3N NaOH was added to pH 10 and extracted twice into dichloromethane. The combined organic extracts were washed with brine, dried (Na_2SO_4) and concentrated in vacuo to give the amidine ester Compound 39 (4.0 g) as a syrup. MS m/z 447(M^+); 447(M^{+2}).

15

Example 6

Following the procedure of Example 5 and substituting the appropriate starting materials, reagents and solvents the following compounds were prepared:

Ex#	MS m/z (MH^+)	MS m/z (MH^{+2})
29	385	387
30	431	---
31	385	387
32	370	---
33	370	---
34	399	401
35	433	435
36	364	---
37	414	---
38	447	449
40	461	463
41	496	---
42	434	---
43	467	469

44	450	—
45	415	417
46	352	—
47	382	—
48	382	—
49	419	421
50	399	401
51	392	—

Biological Examples

δ -opioid and μ -opioid receptor binding for the compounds of the present invention were determined according to the following procedures and the indicated results were obtained.

5 Scintillation Screening Assay for δ -Opioid Receptor Binding

This is a receptor based screen to detect the competitive binding of test compounds at the δ -opioid receptor against the radioligand, [^3H]bremazocine (S.A.=25.5 Ci/mmol, Dupont/NEN, Cambridge, Massachusetts). Unknown compounds that bind to the same receptor as the radioligand will compete for the receptor and reduce the amount of radioligand which binds to the receptor. This is detected as a decreased scintillation signal from that particular incubation. The greater affinity an unknown has for the receptor, the larger the observed decrease in radioligand bound to the receptor; thus the assay is in the format of an inhibition study.

15 **Materials:**

The receptor is a cloned human cDNA expressed in mammalian CHO cells. Membranes prepared from these cells are purchased from Receptor Biology, Baltimore, MD. The reaction buffer is composed as follows: HEPES (50 mM final), $MgCl_2 \cdot 6H_2O$ (5 mM final), o-phenanthroline (20 mg/l), aprotinin (10 mg/l), Pefabloc SC (250 mg/l), leupeptin (0.5 mg/l), pepstatin A (0.7 mg/l), trypsin inhibitor (25 mg/l), chymostatin (10 mg/l), pH = 7.2. Naloxone, 10 μM , is used to define non-specific binding. The assay employs filtration to capture receptor and bound ligand.

Procedure:

The receptor (membrane) preparation (28 ug protein) is allowed to incubate with the opioid receptor radioligand ($[^3\text{H}]$ bremazocine, 2.4 nM) in 96-well plates until equilibrium is reached (>2 hr). Following incubation with the radioligand at 23°C, the well contents are filtered onto 96-well Whatman GF/C filter plates using a Packard cell harvester. Radioligand bound to the receptor also remains on the filter. The filters are rinsed three times with 0.5 mL of physiological saline (0.9% NaCl) to remove any unbound radioligand from the filters. Filters are dried and scintillation fluid is then added to the filters which emits light in proportion to the amount of radioactivity on the filter which is determined using an Packard Topcount scintillation counter. Data are reported as percent inhibition of control binding.

Results:

Table 3 shows the biological activity in % inhibition for 25 μM solutions for a number of the instant compounds in the scintillation assay for δ -opioid receptor binding.

Table 3

δ -Opioid Receptor Binding (% Inhibition)

Cpd	%I @ 25 μM	Cpd	%I @ 25 μM
1	106	13	100
3	103	14	101
4	100	29	97
5	100	30	99
6	103	31	100
7	97	32	97
8	97	33	100
9	97	34	90
10	102	46	94
11	98	47	91
12	98	48	60

Manual Tissue Screening Assay for δ - and μ -Opioid Receptor Binding
Rat Brain δ -Opioid Receptor Binding Assay

The activity of the compounds of the invention as analgesics was demonstrated by the rat brain δ -opioid receptor binding assay as described below.

Procedure

5 Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) are killed by cervical dislocation, and their brains removed and placed immediately in ice cold Tris HCl buffer (50 mM, pH 7.4). The forebrains are separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction. After
10 dissection, the forebrains are homogenized in Tris buffer in a Teflon®-glass homogenizer. The homogenate is diluted to a concentration of 1 g of forebrain tissue per 100 mL Tris buffer and centrifuged at 39,000 X G for 10 min. The pellet is resuspended in the same volume of Tris buffer with several brief pulses from a Polytron homogenizer. This particulate preparation is used for
15 the δ -opioid binding assays. Following incubation with the δ -selective peptide ligand [3 H]DPDPE at 25°C, the tube contents are filtered through Whatman GF/B filter sheets on a Brandel cell harvester. The tubes and filters are rinsed three times with 4 mL of 10 mM HEPES (pH 7.4), and the radioactivity associated with the filter circles determined using Formula 989 scintillation fluid
20 (New England Nuclear, Boston, MA) in a scintillation counter.

Analysis

The data are used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound is evaluated) or a K_i value (when a range of concentrations are tested).

25 % Inhibition was calculated as:

$$1 - \left(\frac{\text{test compound dpm} - \text{nonspecific dpm}}{\text{total dpm} - \text{nonspecific dpm}} \right) \times 100\%$$

K_i value is calculated using the LIGAND (Munson, P.J. and Rodbard, D., Anal. Biochem. 107: 220-239, 1980) data analysis program. Those compounds with K_i values of > 10000 nM are considered to be biologically inactive.

30 Table 4 shows the biological activity in % inhibition for instant compounds as measured in the rat brain δ -opioid receptor binding assay.

Table 4

 δ -Opioid Receptor Binding (K_i nM)

Cpd	K_i nM	Cpd	K_i nM
1	16	29	283
3	62.6	30	638.3
4	57.6	31	221.6
5	39.2	32	259
6	91.1	33	230
7	291.8	34	87.3
8	60.7	35	7640
9	58.5	36	954
10	118	37	1690
11	256	38	246
12	674.5	39	2010
13	277.3	40	> 10000
14	176.8	41	> 10000
15	859	42	> 10000
16	170	43	> 10000
17	212	44	82.6
18	157.4	45	299
19	20.5	51	405
20	11.8	52	487
21	95.3	53	7030
22	764	54	2149
23	1.22	55	1173
24	545	56	396
25	> 10000	57	29.6
26	22.9	58	820
27	53.5	59	101
28	142		

Rat Brain μ -Opioid Receptor Binding Assay

The activity of compounds of the invention as analgesics is

- 5 demonstrated by the rat brain μ -opioid receptor binding assay as described below.

Procedure

Male, Wistar rats (150-250 g, VAF, Charles River, Kingston, NY) are

- killed by cervical dislocation and their brains removed and placed immediately in ice cold Tris HCl buffer (50 mM, pH 7.4). The forebrains are separated from the remainder of the brain by a coronal transection, beginning dorsally at the colliculi and passing ventrally through the midbrain-pontine junction. After
- 5 dissection, the forebrains are homogenized in Tris buffer in a Teflon®-glass homogenizer. The homogenate is diluted to a concentration of 1 g of forebrain tissue per 100 mL Tris buffer and centrifuged at 39,000 X G for 10 min. The pellet is resuspended in the same volume of Tris buffer with several brief pulses from a Polytron homogenizer. This particulate preparation is used for
- 10 the μ -opioid binding assays. Following incubation with the μ -selective peptide ligand [3 H]DAMGO at 25°C, the tube contents are filtered through Whatman GF/B filter sheets on a Brandel cell harvester. The tubes and filters are rinsed three times with 4 mL of 10 mM HEPES (pH 7.4) and the radioactivity associated with the filter circles determined using Formula 989 scintillation fluid
- 15 (New England Nuclear, Boston, MA) in a scintillation counter.

Analysis

- The data are used to calculate either the % inhibition compared to control binding (when only a single concentration of test compound is evaluated) or a K_i value (when a range of concentrations is tested).
- 20 % Inhibition is calculated as:

$$1 - \left(\frac{\text{test compound dpm} - \text{nonspecific dpm}}{\text{total dpm} - \text{nonspecific dpm}} \right) \times 100\%$$

- K_i value is calculated using the LIGAND (Munson, P.J. and Rodbard, D., Anal. Biochem. 107: 220-239, 1980) data analysis program. Those compounds with K_i values of > 10000 nM are considered to be biologically inactive.
- 25 Table 5 shows the biological activity in % inhibition for instant compounds as measured in the rat brain μ -opioid receptor binding assay.

Table 5

 μ -Opioid Receptor Binding (K_i nM)

Cpd	K_i nM	Cpd	K_i nM
1	> 10000	29	> 10000
3	> 10000	30	> 10000
4	> 10000	31	> 10000
5	5510	32	> 10000
6	> 10000	33	> 10000
7	3930	34	2070
8	6890	35	> 10000
9	> 10000	36	> 10000
10	> 10000	37	> 10000
11	> 10000	38	> 10000
12	> 10000	39	> 10000
13	> 10000	40	> 10000
14	9530	41	> 10000
15	> 10000	42	> 10000
16	4330	43	> 10000
17	> 10000	44	9150
18	> 10000	45	> 10000
19	7600	51	> 10000
20	> 10000	52	600
21	> 10000	53	> 10000
22	> 10000	54	1610
23	1200	55	> 10000
24	1000	57	618
25	> 10000	58	232
26	2960	59	197
27	> 10000		
28	> 10000		

Mouse Acetylcholine Bromide-Induced Abdominal Constriction Assay

The activity of compounds of the invention as analgesics was further demonstrated by the mouse acetylcholine bromide-induced abdominal

5 constriction assay as described below.

Procedure

The mouse acetylcholine-induced abdominal constriction assay, as

described by Collier et al. in *Brit. J. Pharmacol. Chem. Ther.*, 32: 295-310, 1968 with minor modifications, was used to assess analgesic potency of the compounds of formula (I). The test drugs or appropriate vehicles were administered orally (p.o.) and 30 min later the animal received an

- 5 intraperitoneal (i.p.) injection of 5.5 mg/kg acetylcholine bromide (Matheson, Coleman and Bell, East Rutherford, NJ). The mice were then placed in groups of three into glass bell jars and observed for a ten min observation period for the occurrence of an abdominal constriction response (defined as a wave of constriction and elongation passing caudally along the abdominal wall, accompanied by a twisting of the trunk and followed by extension of the hind limbs). For compounds of the present invention, the percent inhibition of this response to a nociceptive stimulus (equated to % analgesia) was calculated as follows:

% Inhibition of response (i.e., % analgesia) =

15
$$\left(\frac{\text{No. of CAR} - \text{No. of DTAR}}{\text{No. of CAR}} \right) \times 100\%$$

CAR: Control Animal Responses

DTAR: Drug-Treated Animal Responses

- Table 6 shows the biological activity in % inhibition at a dose of 150 $\mu\text{mole/Kg}$ p.o. for instant compounds as measured in the mouse acetylcholine bromide-induced abdominal constriction (MAIT) assay.
- 20


Table 6
MAIT (% Inhibition)

Cpd	% Inhibition	Cpd	% Inhibition
1	40	16	50
3	40	19	40
4	7.7	20	23.1
5	14.3	21	40
6	20	46	26.7
8	7.1	47	26.7
10	26.7		

- While the foregoing specification teaches the principles of the present invention, with examples provided for the purpose of illustration, it will be
- 5 understood that the practice of the invention encompasses all of the usual variations, adaptations and/or modifications as come within the scope of the following claims and their equivalents.

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



Formula (I)

wherein:

X is a substituent selected from the group consisting of S and O;

Z is a substituent selected from the group consisting of O(R₅) and N(R₆)(R₇);

- 10 the moiety -C(X)Z is substituted on the phenyl at the 3 or 4 position;

n is an integer from 1 to 2;

- 15 R₁ is a substituent selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy(C₁₋₆)alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkyl(C₁₋₆)alkoxycarbonyl, formyl, aryl, aryl(C₁₋₆)alkyl, diaryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl; wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₁₋₄alkoxy, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy;

R₂ and R₃ are substituents independently selected from the group consisting of

hydrogen and C₁₋₆alkyl;

Ar is aryl optionally substituted with one to three substituents selected from R₄;

- R₄ is a substituent selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkoxy, aryl, aryl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, cyano, hydroxy, nitro, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy; alternatively, two R₄ substituents may be fused together on adjacent carbon atoms to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

R₅ is a substituent selected from C₁₋₆alkyl; and,

- 10 R₆ and R₇ are substituents independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₇cycloalkyl, aryl and aryl(C₁₋₆)alkyl, wherein cycloalkyl and aryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₁₋₄alkoxy, C₃₋₇cycloalkyl, trihaloC₁₋₃alkyl and trihaloC₁₋₃alkoxy; alternatively, R₆ and R₇ may be fused together to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

2. The compound of claim 1 wherein X is O.

- 20 3. The compound of claim 1 wherein R₁ is a substituent selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy(C₁₋₆)alkyl, C₁₋₆alkoxycarbonyl, formyl, aryl, aryl(C₁₋₆)alkyl, diaryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl; wherein aryl is optionally substituted with one to three substituents independently selected from halogen and C₁₋₄alkoxy).

- 25 4. The compound of claim 1 wherein R₁ is a substituent selected from the

- group consisting of hydrogen, methyl, ethyl, *n*-propyl, *n*-butyl, *n*-hexyl, allyl, propenyl, cinnamyl, methoxy(C₁₋₃)alkyl, ethoxy(C₁₋₃)alkyl, propoxy(C₁₋₃)alkyl, C₁₋₃alkoxycarbonyl, formyl, phenyl (optionally substituted with one to two substituents independently selected from halogen), benzyl (optionally substituted with one to three substituents independently selected from halogen and C₁₋₄alkoxy), benzhydryl, phenyl(C₂₋₃)alkyl, furyl(C₁₋₃)alkyl, thienyl(C₁₋₃)alkyl, pyrrolyl(C₁₋₃)alkyl, pyrrolinyl(C₁₋₃)alkyl, oxazolyl(C₁₋₃)alkyl, thiazolyl(C₁₋₃)alkyl, imidazolyl(C₁₋₃)alkyl, imidazoliny(C₁₋₃)alkyl, pyrazolyl(C₁₋₃)alkyl, pyrazolinyl(C₁₋₃)alkyl, isoxazolyl(C₁₋₃)alkyl, isothiazolyl(C₁₋₃)alkyl, pyridinyl(C₁₋₃)alkyl, pyridazinyl(C₁₋₃)alkyl, pyrimidinyl(C₁₋₃)alkyl and pyrazinyl(C₁₋₃)alkyl.

5. The compound of claim 1 wherein R₁ is a substituent selected from the group consisting of hydrogen, ethyl, *n*-propyl, allyl, methoxyethyl, phenyl, benzyl, phenethyl and 2-thienylethyl.
6. The compound of claim 1 wherein R₂ and R₃ are substituents independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl and *n*-butyl.
7. The compound of claim 1 wherein R₂ and R₃ are substituents independently selected from the group consisting of hydrogen and methyl.
8. The compound of claim 1 wherein Ar is a substituent selected from the group consisting of phenyl and naphthalenyl optionally substituted with one to three substituents selected from R₄.
9. The compound of claim 1 wherein Ar is phenyl optionally substituted with one to three substituents selected from R₄.
10. The compound of claim 1 wherein R₄ is a substituent selected from the group consisting of halogen, C₁₋₄alkoxy and trihaloC₁₋₄alkyl.

11. The compound of claim 1 wherein R_4 is a substituent selected from the group consisting of chlorine, fluorine, bromine, methoxy, ethoxy, propoxy, butoxy, trifluoromethyl and trifluoroethyl.
12. The compound of claim 1 wherein R_4 is a substituent selected from the group consisting of chlorine, fluorine, bromine, methoxy and trifluoromethyl.
13. The compound of claim 1 wherein R_5 is a substituent selected from the group consisting of methyl, ethyl, *n*-propyl and *n*-butyl.
14. The compound of claim 1 wherein R_5 is methyl.
15. The compound of claim 1 wherein R_6 and R_7 are substituents independently selected from the group consisting of hydrogen and C_{1-6} alkyl.
16. The compound of claim 1 wherein R_6 and R_7 are substituents independently selected from the group consisting of hydrogen, methyl, ethyl, *n*-propyl and *n*-butyl.
17. The compound of claim 1 wherein R_6 and R_7 are substituents independently selected from the group consisting of ethyl and *n*-propyl.
18. The compound of claim 1 selected from the group consisting of:
- N,N-diethyl-4-[(4-ethyl-1-piperazinyl)(phenylimino)methyl]-benzamide;
N,N-diethyl-4-[(4-ethyl-1-piperazinyl)((3-methoxyphenyl)imino)methyl]-benzamide;
- 4-[(3-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-diethyl-benzamide;
4-[(3-bromophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-diethyl-benzamide;
4-[(3-bromophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-dipropyl-benzamide;
- 4-[(2-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-diethyl-benzamide;
4-[(2-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-dipropyl-


- benzamide;
 4-[(4-ethyl-1-piperazinyl)[(3-fluorophenyl)imino]methyl]-N,N-dipropyl-
 benzamide;
 N,N-diethyl-4-[(4-ethyl-1-piperazinyl)[(3-fluorophenyl)imino]methyl]-benzamide;
 5 N,N-diethyl-4-[(4-ethyl-1-piperazinyl)[(2-fluorophenyl)imino]methyl]-benzamide;
 4-[(4-ethyl-1-piperazinyl)[(2-fluorophenyl)imino]methyl]-N,N-dipropyl-
 benzamide;
 4-[(3,5-dichlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-dipropyl-
 benzamide;
 10 4-[(3,5-dichlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-N,N-diethyl-
 benzamide;
 4-[(3-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-N,N-diethyl-
 benzamide;
 N,N-diethyl-4-[(phenylimino)[4-(2-propenyl)-1-piperazinyl]methyl]-benzamide;
 15 4-[(E)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)piperazinyl](phenylimino)methyl]-
 N,N-diethyl-benzamide;
 N,N-diethyl-4-[(phenylimino)[4-(phenylmethyl)-1-piperazinyl]methyl]-benzamide;
 4-[(2-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-N,N-diethyl-
 benzamide;
 20 4-[(2-chlorophenyl)imino][4-(2-propenyl)-1-piperazinyl]methyl]-N,N-diethyl-
 benzamide;
 4-[(2-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-N,N-diethyl-
 benzamide;
 4-[(2-chlorophenyl)imino][4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-N,N-
 25 diethyl-benzamide;
 N,N-diethyl-4-[(phenylimino)[4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-
 benzamide;
 N,N-diethyl-4-[[4-(phenylmethyl)-1-piperazinyl][[2-
 (trifluoromethyl)phenyl]imino]methyl]-benzamide;
 30 N,N-diethyl-4-[[4-(2-phenylethyl)-1-piperazinyl][[2-
 (trifluoromethyl)phenyl]imino]methyl]-benzamide;
 4-[(2-chlorophenyl)imino][4-(2-phenylethyl)-1-piperazinyl]methyl]-N,N-diethyl-
 benzamide;

- N,N-diethyl-4-[[4-(2-methoxyethyl)-1-piperazinyl]][[2-(trifluoromethyl)phenyl]imino]methyl]-benzamide;
4-[[[(2-chlorophenyl)imino][4-(2-methoxyethyl)-1-piperazinyl]methyl]-N,N-diethyl-benzamide;
- 5 4-[[[(4-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-N,N-diethyl-benzamide;
4-[[[(3-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
4-[[[(3-bromophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 10 4-[[[(2-chlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
4-[[[(4-ethyl-1-piperazinyl)][(3-fluorophenyl)imino]methyl]-benzoic acid methyl ester;
- 15 4-[[[(2-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
4-[[[(2-chlorophenyl)imino](4-phenyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
4-[[[(4-ethenyl-1-piperazinyl)(phenylimino)methyl]-benzoic acid methyl ester;
- 20 4-[[[(phenylimino)[4-(phenylmethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
4-[[[(4-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
4-[[[(2-chlorophenyl)imino][4-(phenylmethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 25 4-[[[(2-chlorophenyl)imino][4-(2-phenylethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
4-[[[4-(2-phenylethyl)-1-piperazinyl]][[2-(trifluoromethyl)phenyl]imino]methyl]-benzoic acid methyl ester;
- 30 4-[[[(phenylimino)[4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-benzoic acid methyl ester;
4-[[[(2-chlorophenyl)imino][4-[2-(2-thienyl)ethyl]-1-piperazinyl]methyl]-benzoic acid methyl ester;

- 4-[[4-(2-methoxyethyl)-1-piperazinyl][[2-(trifluoromethyl)phenyl]imino]methyl]-benzoic acid methyl ester;
- 4-[[[(2-chlorophenyl)imino][4-(2-methoxyethyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 5 4-[(4-ethyl-1-piperazinyl)(phenylimino)methyl]-benzoic acid methyl ester;
- 4-[(4-ethyl-1-piperazinyl)[(3-methoxyphenyl)imino]methyl]-benzoic acid methyl ester;
- 4-[(4-ethyl-1-piperazinyl)[(2-methoxyphenyl)imino]methyl]-benzoic acid methyl ester;
- 10 4-[[[(3,5-dichlorophenyl)imino](4-ethyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 4-[[[(3-chlorophenyl)imino](4-propyl-1-piperazinyl)methyl]-benzoic acid methyl ester;
- 4-[(E)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)piperazinyl](phenylimino)methyl]-benzoic acid methyl ester;
- 15 3-[[[(2-chlorophenyl)imino][4-(2-propenyl)-1-piperazinyl]methyl]-N,N-diethylbenzamide;
- N,N-diethyl-3-[(phenylimino)[4-(2-propenyl)-1-piperazinyl]methyl]-benzamide;
- 3-[[[(2-chlorophenyl)imino][4-(2-propenyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- 20 3-[(phenylimino)[4-(2-propenyl)-1-piperazinyl]methyl]-benzoic acid methyl ester;
- N,N-diethyl-4-[[hexahydro-4-(2-phenylethyl)-1H-1,4-diazepin-1-yl](phenylimino)methyl]-benzamide;
- 4-[[[(2-chlorophenyl)imino][hexahydro-4-(2-phenylethyl)-1H-1,4-diazepin-1-yl]methyl]-N,N-diethylbenzamide;
- 25 4-[[hexahydro-4-(2-phenylethyl)-1H-1,4-diazepin-1-yl](phenylimino)methyl]-benzoic acid methyl ester;
- and,
- 4-[[[(2-chlorophenyl)imino][hexahydro-4-(2-phenylethyl)-1H-1,4-diazepin-1-yl]methyl]-benzoic acid methyl ester;
- 30

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

19. The compound of claim 1 of the formula:



wherein n, R₁, R₂, R₃, R₄ and X are selected from the group consisting of:

n	R ₁	R ₂	R ₃	R ₄	-C(O)X
1	Et	H	H	---	-4-C(O)N(Et) ₂ ;
1	Et	H	H	3-MeO	-4-C(O)N(Et) ₂ ;
1	Et	H	H	3-Cl	-4-C(O)N(Et) ₂ ;
1	Et	H	H	3-Br	-4-C(O)N(Et) ₂ ;
1	Et	H	H	3-Br	-4-C(O)N(Pr) ₂ ;
1	Et	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
1	Et	H	H	2-Cl	-4-C(O)N(Pr) ₂ ;
1	Et	H	H	3-F	-4-C(O)N(Pr) ₂ ;
1	Et	H	H	3-F	-4-C(O)N(Et) ₂ ;
1	Et	H	H	2-F	-4-C(O)N(Et) ₂ ;
1	Et	H	H	2-F	-4-C(O)N(Pr) ₂ ;
1	Et	H	H	3,5-Cl ₂	-4-C(O)N(Pr) ₂ ;
1	Et	H	H	3,5-Cl ₂	-4-C(O)N(Et) ₂ ;
1	Pr	H	H	3-Cl	-4-C(O)N(Et) ₂ ;
1	Allyl	H	H	---	-4-C(O)N(Et) ₂ ;
1	Allyl	2-Me	5-Me	---	-4-C(O)N(Et) ₂ ;
1	Benzyl	H	H	---	-4-C(O)N(Et) ₂ ;
1	Allyl	H	H	3-Cl	-4-C(O)N(Et) ₂ ;
1	Allyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
1	Benzyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;

1	2-(2-thienyl)ethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
1	2-(2-thienyl)ethyl	H	H	—	-4-C(O)N(Et) ₂ ;
1	Benzyl	H	H	2-CF ₃	-4-C(O)N(Et) ₂ ;
1	Phenethyl	H	H	2-CF ₃	-4-C(O)N(Et) ₂ ;
1	Phenethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
1	2-(methoxy)ethyl	H	H	2-CF ₃	-4-C(O)N(Et) ₂ ;
1	2-(methoxy)ethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
1	Benzyl	H	H	4-Cl	-4-C(O)N(Et) ₂ ;
1	Et	H	H	3-Cl	-4-C(O)OMe;
1	Et	H	H	3-Br	-4-C(O)OMe;
1	Et	H	H	2-Cl	-4-C(O)OMe;
1	Et	H	H	3-F	-4-C(O)OMe;
1	Et	H	H	2-F	-4-C(O)OMe;
1	Pr	H	H	2-Cl	-4-C(O)OMe;
1	Ph	H	H	2-Cl	-4-C(O)OMe;
1	Allyl	H	H	—	-4-C(O)OMe;
1	Benzyl	H	H	—	-4-C(O)OMe;
1	Benzyl	H	H	4-Cl	-4-C(O)OMe;
1	Benzyl	H	H	2-Cl	-4-C(O)OMe;
1	Phenethyl	H	H	2-Cl	-4-C(O)OMe;
1	Phenethyl	H	H	2-CF ₃	-4-C(O)OMe;
1	2-(2-thienyl)ethyl	H	H	—	-4-C(O)OMe;
1	2-(2-thienyl)ethyl	H	H	2-Cl	-4-C(O)OMe;
1	2-(methoxy)ethyl	H	H	2-CF ₃	-4-C(O)OMe;
1	2-(methoxy)ethyl	H	H	2-Cl	-4-C(O)OMe;
1	Et	H	H	—	-4-C(O)OMe;
1	Et	H	H	3-MeO	-4-C(O)OMe;
1	Et	H	H	2-MeO	-4-C(O)OMe;
1	Et	H	H	3,5-Cl ₂	-4-C(O)OMe;
1	Pr	H	H	3-Cl	-4-C(O)OMe;
1	Allyl	2-Me	5-Me	—	-4-C(O)OMe;
1	Allyl	H	H	2-Cl	-3-C(O)N(Et) ₂ ;
1	Allyl	H	H	—	-3-C(O)N(Et) ₂ ;

1	Allyl	H	H	2-Cl	-3-C(O)OMe;
1	Allyl	H	H	---	-3-C(O)OMe;
2	Phenethyl	H	H	---	-4-C(O)N(Et) ₂ ;
2	Phenethyl	H	H	2-Cl	-4-C(O)N(Et) ₂ ;
2	Phenethyl	H	H	---	-4-C(O)OMe;
and,					
2	Phenethyl	H	H	2-Cl	-4-C(O)OMe;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

20. The compound of claim 1 which is an effective δ -opioid receptor modulator.


21. The compound of claim 1 which is an effective δ -opioid receptor agonist.

5 22. The compound of claim 1 which is an effective analgesic.

23. The compound of claim 1 which is an effective δ -opioid receptor antagonist.

24. The compound of claim 1 which are effective immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and
 10 psychiatric conditions, medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases.

25. A pharmaceutical composition comprising a compound of Formula (I):



Formula (I)

wherein:

X is a substituent selected from the group consisting of S and O;

- 5 Z is a substituent selected from the group consisting of O(R₅) and N(R₆)(R₇);

the moiety -C(X)Z is substituted on the phenyl at the 3 or 4 position;

n is an integer from 1 to 2;

- R₁ is a substituent selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy(C₁₋₆)alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkyl(C₁₋₆)alkoxycarbonyl, formyl, aryl, aryl(C₁₋₆)alkyl, diaryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl; wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₁₋₄alkoxy, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy;
- 10

- 15 R₂ and R₃ are substituents independently selected from the group consisting of hydrogen and C₁₋₆alkyl;

Ar is aryl optionally substituted with one to three substituents selected from R₄;

R₄ is a substituent selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkoxy, aryl, aryl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, cyano, hydroxy, nitro, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy; alternatively, two R₄ substituents may be fused together on adjacent carbon atoms to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

R₅ is a substituent selected from C₁₋₆alkyl; and,

R₆ and R₇ are substituents independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₇cycloalkyl, aryl and aryl(C₁₋₆)alkyl, wherein cycloalkyl and aryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₁₋₄alkoxy, C₃₋₇cycloalkyl, trihaloC₁₋₃alkyl and trihaloC₁₋₃alkoxy; alternatively, R₆ and R₇ may be fused together to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

and pharmaceutically acceptable enantiomers, diastereomers and salts thereof and a pharmaceutically acceptable carrier.


26. A method for preparing the pharmaceutical composition of claim 25 comprising mixing a compound of claim 25 and a pharmaceutically acceptable carrier.

27. The pharmaceutical composition of claim 25 further comprising a combination of a compound of claim 25 and a compound effective as a μ -opioid modulator.

28. The pharmaceutical composition of claim 27 wherein the compound effective as a μ -opioid modulator is selected from the group consisting of alfentanil, allylprodine, alphaprodine, anileridine, benzyl-morphine, bezitramide,

- buprenorphine, butorphanol, clonitazene, cyclazocine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl, heroin, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacymorphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine, propiram, propoxyphene, sufentanil, tilidine, tramadol, salts thereof, complexes thereof; and mixtures of any of the foregoing.

29. A method for treating a disorder modulated by the δ -opioid receptor in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):



Formula (I)

- wherein:

X is a substituent selected from the group consisting of S and O;

Z is a substituent selected from the group consisting of O(R₅) and N(R₆)(R₇);

the moiety -C(X)Z is substituted on the phenyl at the 3 or 4 position;

n is an integer from 1 to 2;

- 5 R₁ is a substituent selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy(C₁₋₆)alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkyl(C₁₋₆)alkoxycarbonyl, formyl, aryl, aryl(C₁₋₆)alkyl, diaryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl; wherein aryl and heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₄alkyl, C₁₋₄alkoxy, amino, C₁₋₄alkylamino, 10 di(C₁₋₄alkyl)amino, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy;

R₂ and R₃ are substituents independently selected from the group consisting of hydrogen and C₁₋₆alkyl;

Ar is aryl optionally substituted with one to three substituents selected from R₄;

- 15 R₄ is a substituent selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkoxy, aryl, aryl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, cyano, hydroxy, nitro, trihaloC₁₋₄alkyl and trihaloC₁₋₄alkoxy; alternatively, two R₄ substituents may be fused together on adjacent carbon atoms to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

- 20 R₅ is a substituent selected from C₁₋₆alkyl; and,

R₆ and R₇ are substituents independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₇cycloalkyl, aryl and aryl(C₁₋₆)alkyl, wherein cycloalkyl and aryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen,

C₁₋₄alkyl, C₂₋₄alkenyl, C₁₋₄alkoxy, C₃₋₇cycloalkyl, trihaloC₁₋₃alkyl and trihaloC₁₋₃alkoxy; alternatively, R₆ and R₇ may be fused together to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-;

- 5 and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.
30. The method of claim 29 wherein the therapeutically effective amount of the compound of claim 29 is from about 0.01 mg/day to about 12,000 mg/day.
31. The method of claim 29 wherein the disorder is pain modulated by a therapeutically effective amount of a compound of claim 29.
- 10 32. The method of claim 29 wherein the disorder is selected from the group consisting of immune disorders, inflammation, neurological conditions, psychiatric conditions, drug abuse, alcohol abuse, gastritis, diarrhea, cardiovascular disorders and respiratory disorders modulated by a therapeutically effective amount of a compound of claim 29.
- 15 33. The method of claim 29 further comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition of claim 25.
34. The method of claim 33 wherein the therapeutically effective amount of the pharmaceutical composition of claim 25 is from about 0.01 mg/day to about 12,000 mg/day.

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 June 2002 (20.06.2002)

PCT

(10) International Publication Number
WO 02/048122 A3(51) International Patent Classification⁷: C07D 295/155,
241/04, 333/20, A61K 31/495, 31/381, A61P 25/04(74) Agents: JOHNSON, Philip, S. et al.; Johnson & Johnson,
One Johnson & Johnson Plaza, New Brunswick, NJ 08933
(US).

(21) International Application Number: PCT/US01/47894

(22) International Filing Date:
11 December 2001 (11.12.2001)

(25) Filing Language: English

(26) Publication Language: English


(30) Priority Data:
60/255,658 14 December 2000 (14.12.2000) US(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL,
INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ
08869-0602 (US).(72) Inventors: BAXTER, Ellen, W.; 148 North Keswick Av-
enue, Glenside, PA 19038 (US). NORTEY, Samuel, O.;
7423 Euston Road, Elkins Park, PA 19027 (US). REITZ,
Allen, B.; 109 Greenbriar Road, Lansdale, PA 19446 (US).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA,
ZM, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: BENZAMIDINE DERIVATIVES



(57) Abstract: Benzamidine derivatives of the formula I are useful delta-opioid receptor modulators, agonists useful as analgesics and antagonists useful as immunosuppressants, antiinflammatory agents, agents for the treatment of neurological and psychiatric conditions medicaments for drug and alcohol abuse, agents for treating gastritis and diarrhea, cardiovascular agents and agents for the treatment of respiratory diseases. Wherein: X is a substituent selected from the group consisting of S and O; Z is a substituent selected from the group consisting of O(R₅) and N(R₆)(R₇); the moiety -C(X)Z is substituted on the phenyl at the 3 or 4 position; n is an integer from 1 to 2; R₁ is a substituent selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy(C₁₋₆)alkyl, C₁₋₆alkoxycarbonyl, C₁₋₆alkyl(C₁₋₆)alkoxycarbonyl, formyl, aryl, aryl(C₁₋₆)alkyl, diaryl(C₁₋₆)alkyl and heteroaryl(C₁₋₆)alkyl; wherein aryl and

heteroaryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkoxy, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, trihaloC₁₋₆alkyl and trihaloC₁₋₆alkoxy; R₂ and R₃ are substituents independently selected from the group consisting of hydrogen and C₁₋₆alkyl; Ar is aryl optionally substituted with one to three substituents selected from R₄; R₄ is a substituent selected from the group consisting of halogen, C₁₋₆alkyl, C₁₋₆alkoxy, aryl, aryl(C₁₋₆)alkyl, heteroaryl, heteroaryl(C₁₋₆)alkyl, amino, C₁₋₆alkylamino, di(C₁₋₆alkyl)amino, cyano, hydroxy, nitro, trihaloC₁₋₆alkyl and trihaloC₁₋₆alkoxy; alternatively, two R₄ substituents may be fused together on adjacent carbon atoms to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and -O(CH₂)₁₋₃O-; R₅ is a substituent selected from C₁₋₆alkyl; and R₆ and R₇ are substituents independently selected from the group consisting of hydrogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆cycloalkyl, aryl and aryl(C₁₋₆)alkyl, wherein cycloalkyl and aryl are optionally substituted with one to three substituents independently selected from the group consisting of halogen, C₁₋₆alkyl, C₂₋₆alkenyl, C₁₋₆alkoxy, C₃₋₇cycloalkyl, trihaloC₁₋₆alkyl and trihaloC₁₋₆alkoxy; alternatively, R₆ and R₇ may be fused together to form a single fused moiety, wherein the moiety is selected from the group consisting of -(CH₂)₃₋₅- and O(CH₂)₁₋₃O-; and pharmaceutically acceptable enantiomers, diastereomers and salts thereof.

WO 02/048122 A3



(88) Date of publication of the international search report:
12 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D295/155 C07D241/04 C07D333/20 A61K31/495 A61K31/381
A61P25/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 23466 A (PLOBECK NIKLAS ;ROBERTS EDWARD (CA); ASTRA PHARMA INC (CA); WAHLES) 3 July 1997 (1997-07-03) cited in the application the whole document	1-34
A	WO 98 28270 A (ROBERTS EDWARD ;ASTRA PHARMA INC (CA); ASTRA AB (SE); PELCMAN BENJ) 2 July 1998 (1998-07-02) cited in the application the whole document	1-34
A	WO 98 28275 A (WEI ZHONGYONG ;DELORME DANIEL (CA); ROBERTS EDWARD (CA); ASTRA PHA) 2 July 1998 (1998-07-02) cited in the application the whole document	1-34

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

15 May 2002

Date of mailing of the international search report

18/06/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Scruton-Evans, I

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 15062 A (WELLCOME FOUND) 5 August 1993 (1993-08-05) cited in the application especially page 10, formula II the whole document	1-34
A	US 3 793 322 A (SHROFF J ET AL) 19 February 1974 (1974-02-19) cited in the application see definitions of R and R'	1-34
A	THOMAS J B ET AL: "4-(8-Alkyl-8-azabicyclo[3.2.1]octyl-3-yl)-3-arylanilino-N,N-diethyl benzami des: high affinity, selective ligands for the delta opioid receptor illustrate factors important to antagonist activity" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 11, June 2000 (2000-06), pages 1281-1284, XP004200575 ISSN: 0960-894X cited in the application the whole document	1-34
P,X	NORTEY, S. O. ET AL: "Piperazinyl benzamidines: Synthesis and affinity for the delta opioid receptor" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2001), 11(13), 1741-1743 , 9 July 2001 (2001-07-09), XP002198887 the whole document	1-34
Y	WO 99 33806 A (FITZPATRICK LOUIS J ;CARSON JOHN R (US); REITZ ALLEN B (US); CARMO) 8 July 1999 (1999-07-08) see especially pages 20-24 the whole document	1-34

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/47894

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9723466	A	03-07-1997	AU 715547 B2	03-02-2000
			AU 1216297 A	17-07-1997
			BR 9612204 A	13-07-1999
			CN 1209124 A	24-02-1999
			CZ 9801768 A3	16-09-1998
			EE 9800194 A	15-12-1998
			EP 0915855 A1	19-05-1999
			HU 9901304 A2	30-08-1999
			JP 2000502679 T	07-03-2000
			NO 982807 A	19-08-1998
			NZ 324887 A	28-01-2000
			PL 327403 A1	07-12-1998
			WO 9723466 A1	03-07-1997
			SK 82298 A3	04-11-1998
			TR 9801180 T2	21-10-1998
			US 6130222 A	10-10-2000
			ZA 9610352 A	23-06-1997
WO 9828270	A	02-07-1998	AU 738002 B2	06-09-2001
			AU 5351398 A	17-07-1998
			BR 9713785 A	08-02-2000
			CZ 9902200 A3	17-11-1999
			EE 9900261 A	15-02-2000
			EP 0946510 A1	06-10-1999
			HU 0000613 A2	28-09-2000
			JP 2001507021 T	29-05-2001
			NO 993023 A	12-08-1999
			PL 334370 A1	28-02-2000
			WO 9828270 A1	02-07-1998
			SK 76399 A3	18-01-2000
			TR 9901411 T2	21-09-1999
			US 6153626 A	28-11-2000
			ZA 9711049 A	22-06-1998
WO 9828275	A	02-07-1998	AU 737999 B2	06-09-2001
			AU 5351298 A	17-07-1998
			BR 9714055 A	09-05-2000
			CN 1246111 A	01-03-2000
			CZ 9902199 A3	17-11-1999
			EE 9900256 A	15-12-1999
			EP 0946511 A1	06-10-1999
			JP 2001507350 T	05-06-2001
			NO 993022 A	20-08-1999
			PL 334374 A1	28-02-2000
			WO 9828275 A1	02-07-1998
			SK 76299 A3	08-11-1999
			TR 9901417 T2	21-10-1999
			US 6187792 B1	13-02-2001
			US 2001021715 A1	13-09-2001
			ZA 9711059 A	22-06-1998
			HU 0000610 A2	28-09-2000
WO 9315062	A	05-08-1993	AU 675928 B2	27-02-1997
			AU 3457393 A	01-09-1993
			CA 2129046 A1	05-08-1993
			EP 0649414 A1	26-04-1995
			WO 9315062 A1	05-08-1993
			IL 104582 A	30-10-1998

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/US 01/47894

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9315062	A		JP 3109832 B2	20-11-2000
			JP 7503247 T	06-04-1995
			NZ 246916 A	27-08-1996
			US 5658908 A	19-08-1997
			US 5681830 A	28-10-1997
			US 5574159 A	12-11-1996
			US 5854249 A	29-12-1998
			ZA 9300717 A	02-08-1994
US 3793322	A	19-02-1974	BE 800291 A1	30-11-1973
WO 9933806	A	08-07-1999	AU 2009799 A	19-07-1999
			CA 2316341 A1	08-07-1999
			EP 1049676 A1	08-11-2000
			JP 2001527068 T	25-12-2001
			WO 9933806 A1	08-07-1999
			ZA 9811842 A	23-06-2000

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.